Barclays downgraded shares of Moderna (NASDAQ:MRNA – Free Report) from an overweight rating to an equal weight rating in a report published on Tuesday, Ratings reports. The firm currently has $45.00 ...
China is starting to see a rebound in M&As as government stimulus measures start to bear fruit and pressure from Donald Trump ...
EPS estimates but beats revenue expectations. Barclays downgrades stock, citing COVID demand decline and RSV uptake ...
CSL and Cochlear are two of Australia’s blue-chip healthcare stocks, stalwarts of many investors portfolios, whereas Pro ...
Investors seeking to outperform the market should focus their stock-picking efforts on volatile names in the consumer ...
Please be advised, today's conference is being recorded. I would now like to hand the conference over to your speaker today, Lavina Talukdar. Please go ahead. Thank you, Kevin. Good morning, everyone, ...
The Dow Jones Industrial Average shed 165.35 points, or 0.37%, closing at 44,546.08. The S&P 500 ticked down 0.01% to ...
Shares of Roku Inc (NASDAQ:ROKU) are up 14.5% in premarket trading, after the streaming giant shared smaller-than-expected ...
Moderna (NASDAQ:MRNA – Get Free Report) is expected to be issuing its quarterly earnings data before the market opens on Friday, February 14th. Analysts expect the company to announce earnings of ($2.
Moderna (MRNA), once a pandemic-era darling, has seen its stock plummet 65% over the past year, battered by fading vaccine ...
Star portfolio manager Cathie Wood’s Ark Investment Management filed its 13F holdings report for the fourth quarter on Feb. 4 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results